Septerna, Inc.
NASDAQ:SEPNBiotechnology
-$0.73 today
- Market cap
- $1.88B
- Beta
- 2.38
- P/E (TTM)
- -43.6
- EPS (TTM)
- -$0.81
Volume 0.30M
Average 0.32M
SEPN Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Septerna, Inc.NASDAQ: SEPN
Research & Development · Q3 FY2026 · quarter ended Sep 2026
Research & development grows, but more slowly than its trailing trend
Q3 FY2026 research & development of $36.56M rose 50.7% year over year, behind the +56.0% change in trailing-twelve-month research & development. Sequentially, it rose 4.1% from the prior quarter.
Context
- Research & development amounted to 212.4% of revenue in FY2025, down 5865.5 pp from a year earlier.
- Research & development increased in 2 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
What to watch
Whether quarterly growth recovers from +50.7% toward the trailing-twelve-month pace of +56.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 97.58M USD
- Year-over-year change
- +49.4%
- 2-year CAGR
- +64.7%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 97.58M | +49.4% |
| FY2024 | 2024-12-31 | 65.34M | +81.6% |
| FY2023 | 2023-12-31 | 35.98M | — |
Research & Development vs competitors
How SEPN compares with its peers on the latest reported figures
- SEPN's LTM Sep 2026 research & development of $132.66M is the 2nd highest of the 7 companies compared; the peer median is $105.19M.
- Its year-over-year change of +56.0% is the 3rd highest of 6, against a peer median of +35.7%.
- Research & development amounts to 137.8% of revenue for SEPN, versus a peer median of 319.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $294.44M | +79.9% | +83.9% | — | |
SEPNSepterna, Inc. | LTM Sep 2026 | $132.66M | +56.0% | — | 137.8% |
| LTM Mar 2026 | $114.57M | +28.4% | +7.1% | 572.9% | |
KLRAKailera Therapeutics, Inc. | FY2025 | $109.11M | — | — | — |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $101.27M | +35.7% | +54.7% | — |
| LTM Mar 2026 | $48.2M | -55.0% | -0.4% | — | |
| LTM Mar 2026 | $24.01M | +104.7% | +13.1% | 65.2% | |
| Peer median (excluding SEPN) | $105.19M | +35.7% | +13.1% | 319.0% | |
Competitors are the stored peer set for SEPN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Revenue | 151K | 1.08M | 45.95M |
| Cost of Revenue | 0 | 0 | 0 |
| Gross Profit | 151K | 1.08M | 45.95M |
| Gross Margin | 100.0% | 100.0% | 100.0% |
| Research & Development | 35.98M | 65.34M | 97.58M |
| Selling, General & Admin | 9.72M | 16.56M | 29.16M |
| Operating Expenses | (1.92M) | 81.9M | 126.75M |
| Depreciation & Amortization | 848K | 1.4M | 1.6M |
| EBITDA | (44.7M) | (70.9M) | (47.26M) |
| EBITDA Margin | -29604.0% | -6594.9% | -102.9% |
| Operating Income | 2.08M | (80.82M) | (80.8M) |
| Operating Margin | 1374.2% | -7518.4% | -175.8% |
| Interest Income | 2.79M | 8.62M | 19.53M |
| Interest Expense | 0 | 0 | 0 |
| Other Income / Expenses | 2.8M | 8.53M | 31.93M |
| Income Before Tax | 4.87M | (72.3M) | (48.87M) |
| Pre-Tax Margin | 3225.8% | -6725.2% | -106.3% |
| Income Tax Expense | 691K | (498K) | 12K |
| Net Income | 4.18M | (71.8M) | (48.88M) |
| Net Margin | 2768.2% | -6678.9% | -106.4% |
| EPS (Basic) | 0.03 | (1.93) | (1.10) |
| EPS (Diluted) | 0.03 | (1.93) | (1.10) |
| Weighted Avg Shares | 19.5M | 37.19M | 44.26M |
| Weighted Avg Shares (Diluted) | 19.5M | 37.19M | 44.26M |
Septerna, Inc.
NASDAQ:SEPN
Intrinsic Alpha fair value
Locked
Current Price
$39.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.